- OncoSil Medical (OSL) makes further commercial progress in Spain with its namesake OncoSil brachytherapy device for the treatment of pancreatic cancer
- The company says the first patient treated with OncoSil in Spain has undergone successful surgical resection of their primary tumour
- Meanwhile, the Spanish Ministry of Health approved a tender for Las Palmas Hospital — where OncoSil is treating patients — for €220,000 (A$361,000)
- OncoSil has expanded the number of hospitals treating patients with the OncoSil device, with six hospitals now in active patient treatments
- The news comes alongside a data read-out of 49 patients implanted with the OncoSil device in Australia and New Zealand between August 2017 and January 2023
- OSL shares are up 20 per cent and trading at 1.2 cents at midday AEST
Oncosil Medical (OSL) has made further commercial progress in Spain with its namesake OncoSil brachytherapy device for the treatment of pancreatic cancer.
The company said the first patient treated with OncoSil in Spain had undergone successful surgical resection of their primary tumour. The OncoSil device is a targeted radioactive isotope implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
OSL said patients who underwent successful resections of their primary tumour showed “dramatically” improved outcomes.
“We are pleased that further patients have undergone resection of their tumours after receiving the Oncosil device for the treatment of locally advanced pancreatic cancer (LAPC),” OSL CEO and Managing Director Nigel Lange said.
“In the PanCO trial, 23.8 per cent of patients who were treated with the Oncosil device were successfully resected, and we are encouraged to see this trend continue.”
Meanwhile, the Spanish Ministry of Health approved a tender for Las Palmas Hospital — where OncoSil is treating patients — for €220,000 (A$361,000).
OncoSil has expanded the number of hospitals treating patients with the OncoSil device, with six hospitals now in active patient treatments.
“I am also pleased with the addition of the sixth hospital in Spain, Vall d’Hebron, for the treatment of patients with LAPC,” Mr Lange said.
“We continue to work with additional institutions in Spain and throughout Europe to accelerate the use of the Oncosil device for patients suffering from LAPC.”
Vall d’Hebron Hospital is now active with patient treatments as OSL continues to work with several other institutions in Spain to enable increased patient access to treatment with the Oncosil device.
Today’s Spanish news comes alongside a data read-out of 49 patients implanted with the OncoSil device in Australia and New Zealand between August 2017 and January 2023.
Of the patients treated, 31 per cent had tumour downstaging and were “technically resectable”, according to OSL.
OSL shares were up 20 per cent and trading at 1.2 cents at midday AEST.